DAN MCLEAN, COMMUNICATIONS DIRECTOR, CROHN'S AND
COLITIS UK.
In the VISIBLE 1 trial conducted in 216 adult patients with moderately to severely active ulcerative
colitis, clinical response was obtained at week 6 following two doses of open-label intravenous administrations of vedolizumab as an induction therapy at weeks 0 and 2[i].
Health care providers should avoid prescribing tofacitinib for patients who may have a higher risk of thrombosis, and use tofacitinib at the lowest effective dose or limit the duration of the 10 mg twice daily dosage when treating ulcerative
colitis.
There are also some less common types of IBD which you can find out about on the Crohn's and
Colitis UK website.
Ulcerative
colitis is a chronic disease caused by inflammation of the large intestine and the symptoms are characterised by blood- and mucus-mixed diarrhea, frequent stools, abdominal pain, fever, weight loss and anemia.
Among patients with ulcerative
colitis, more moderate use of strong opioids (one to three prescriptions annually) also significantly correlated with all-cause mortality (HR, 2.
Results from the Phase 3 UNIFI study evaluating the efficacy and safety of STELARA as a maintenance therapy in patients with moderate to severe ulcerative
colitis who were in clinical response to a single intravenous induction of STELARA.
Patients diagnosed with ulcerative
colitis during childhood had 2.5-times higher risk of developing cancer and a 3.7-times higher risk of dying during follow-up compared with the general population.
Forty mice were randomly assigned into five groups: normal control group (group A),
colitis model group (group B), low-dose intervention group (group C), moderate-dose intervention group (group D), and large-dose intervention group (group E).
According to the company, TJ301 is a phase II, randomised, double-blind, placebo-controlled study that is being conducted in multiple sites across China, South Korea and Taiwan area to evaluate the safety and efficacy of TJ301 administered intravenously in patients with active ulcerative
colitis.
A study done on 32 patients with histologically proven collagenous
colitis revealed the presence of chronic constipation in 18 individuals, all of whom responded (improvement in stool frequency) to budesonide, which is a first-line treatment of microscopic
colitis.4 This study also revealed increased prevalence of food allergies in patients with collagenous
colitis, which explains the paradox of diarrhoea-constipation and response to steroids.
The stats emerged in an independent OnePoll study of 1,000 employed adults, commissioned by national charity Crohn's &
Colitis UK.
